Please login to the form below
autoimmune disease
This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.
Citryll snares €15m backing for its autoimmune disease NETs
In some autoimmune disease such as lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis, it is thought that NETs inadvertently react to host cells, stimulating the release ... Other companies including Bristol-Myers
Latest news
-
Alexion's Soliris adds new approval in rare disease NMOSD
First ever drug approved for rare autoimmune disease. Alexion has gained a new FDA approved used for its rare disease blockbuster Soliris. ... NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal
-
Swedish biotech Calliditas signs China licensing deal for autoimmune candidate
the chronic autoimmune kidney disease IgA Nephropathy (IgAN). ... While IgAN is an orphan disease in the US and Europe, its prevalence is much higher in China.
-
Genentech forges $800m autoimmune alliance with Parvus
Genentech will work with Parvus to use its Navacim platform to develop candidates for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease, and between Genentech and Novartis, all of Parvus’ ... One key characteristic of the
-
Genfit claims FDA breakthrough status for liver disease drug
Elafibranor up for speedy US review. Genfit’s most advanced liver disease drug elafibranor has today achieved a breakthrough tag from the US FDA following positive data from a phase 2 ... However, today’s breakthrough designation for elafibranor is
-
Genfit launches $135m IPO to back NASH plans
fund a phase 4 post-marketing study in patients with the liver disease. ... Another $35m earmarked for pivotal trials in primary biliary cirrhosis, a rare autoimmune disease of the liver, while $15m will go on developing Genfit’s commercial operations
More from news
Approximately 3 fully matching, plus 60 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 2)
ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.
-
Managing medication non-adherence
Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to
-
Reaching new heights
Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020
-
Pharma deals during May 2014
Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of
-
The distressing impact of rare diseases
The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease
-
Akari Therapeutics strengthens board
His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop
-
David Horn Solomon takes the helm of Akari Therapeutics
biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.
-
Caldan Therapeutics appoints CEO
Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca
-
Santhera CEO Klaus Schollmeier joins SuppreMol
In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
THE OTHER SIDE OF… CROHN’S DISEASE
Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... She believes that they follow a “by-the-book” mentality, not
-
What next for the treatment of Psoriasis in Europe?
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. ... A chronic autoimmune disease, psoriasis has an estimated
More from PMHub
Approximately 2 fully matching, plus 6 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Atlantis Healthcare
Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
